EXHIBIT 99.02 | |
Notification of major interests in shares
22 March 2007
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:
Shire plc
2. Reason for the notification | State Yes/No |
An acquisition or disposal of voting rights | |
An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | |
An event changing the breakdown of voting rights | |
Other (please specify): Revised due to DTR rules - see Section 13 | Yes |
3. Full name of person(s) subject to the notification obligation: | FMR Corp |
4. Full name of shareholder(s) (if different from 3.): | See attached schedule |
5. Date of the transaction (and date on which the threshold is crossed or reached if different): | Revised due to DTR rules |
6. Date on which issuer notified: | 22 March 2007 |
7. Threshold(s) that is/are crossed or reached: | N/A |
8. Notified details: |
A: Voting rights attached to shares
Class/type of shares if possible using the ISIN CODE | Situation previous to the Triggering transaction | Resulting situation after the triggering transaction | |||||
Number of Shares | Number of Voting Rights | Number of shares | Number of voting rights | % of voting rights |
Direct | Direct | Indirect | Direct | Indirect | |||
GB00B0KQX869 | 16,231,254 | 16,231,254 | 16,231,254 | 2.92%% | |||
B: Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument | Expiration date | Exercise/Conversion Period/ Date | Number of voting rights that may be acquired if the instrument is exercised/converted | % of voting rights |
Total (A+B) | |
Number of voting rights | % of voting rights |
16,231,254 | 2.92% |
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are
effectively held, if applicable:
See attached schedule |
Proxy Voting:
10. Name of the proxy holder: | FMR Corp |
11. Number of voting rights proxy holder will cease to hold: | N/A |
12. Date on which proxy holder will cease to hold voting rights: | N/A |
13. Additional information: | As discussed with the FSA, prior to the implementation of the EU Transparency Directive, we aggregated the interests in the shares of FMR Corp (FMR) and Fidelity International Limited (FIL) together for the purposes of shareholder reporting. According to the new DTR rules we are now reporting the indirect holdings of FMR and FIL separately. A separate notification is being submitted for FIL. Please note these holdings are correct as of close of business 20 March 2007. |
14. Contact name: | Sophie Hughes |
15. Contact telephone number: | fil-regulatoryreporting@uk.fid-intl.com |
(Contact at Shire plc: Vivienne Hemming, Deputy Company Secretary, 01256 894276)
Schedule:
Shares Held | Nominee | Management Company |
846,920 173,000 30,380 99,054 19,300 107,400 45,400 64,300 79,300 98,300 10,026,900 4,474,900 36,100 130,000 | STATE STREET BANK AND TR CO STATE STREET BANK AND TR CO STATE STREET BANK AND TR CO STATE STREET BANK AND TR CO NORTHERN TRUST LONDON NORTHERN TRUST CO MELLON BANK N.A. MELLON BANK N.A. JPMORGAN CHASE BANK JPMORGAN CHASE BANK JPMORGAN CHASE BANK BROWN BROTHERS HARRIMAN AND CO BANK OF NEW YORK BANK OF NEW YORK | FMTC FMRCO FMR FICL FMRCO FMTC FMTC FMRCO FPM FMTC FMRCO FMRCO FMRCO FMTC |
FMR Corp is the parent holding company of Fidelity Management and Research Company (FMRCO), investment manager for US mutual funds and Fidelity Management Trust Company (FMTC), a US state chartered bank which acts as trustee or investment manager of various pension and trust accounts.
For further information please contact:
Investor Relations | Cléa Rosenfeld (Rest of the World) | +44 1256 894 160 |
Eric Rojas (North America) | +1 484 595 8252 |
Notes to editors
SHIRE PLC
Shire’s strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.
Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.
For further information on Shire, please visit the Company’s website: www.shire.com.